Compounds > 2-(4-morpholinoanilino)-6-cyclohexylaminopurine
Page last updated: 2024-09-05

2-(4-morpholinoanilino)-6-cyclohexylaminopurine and pyrazolanthrone

2-(4-morpholinoanilino)-6-cyclohexylaminopurine has been researched along with pyrazolanthrone in 3 studies

Compound Research Comparison

Studies
(2-(4-morpholinoanilino)-6-cyclohexylaminopurine)		Trials
(2-(4-morpholinoanilino)-6-cyclohexylaminopurine)		Recent Studies (post-2010)
(2-(4-morpholinoanilino)-6-cyclohexylaminopurine)		Studies
(pyrazolanthrone)		Trials
(pyrazolanthrone)		Recent Studies (post-2010) (pyrazolanthrone)
850621,4842765

Protein Interaction Comparison

ProteinTaxonomy2-(4-morpholinoanilino)-6-cyclohexylaminopurine (IC50)pyrazolanthrone (IC50)
Chain A, Mitogen-activated protein kinase 10Homo sapiens (human)0.15
Chain A, Mitogen-activated protein kinase 10Homo sapiens (human)0.15
Chain A, Mitogen-activated protein kinase 10Homo sapiens (human)0.15
TPA: protein transporter TIM10Saccharomyces cerevisiae S288C20.2
TPA: protein transporter TIM23Saccharomyces cerevisiae S288C6.31
Serine/threonine-protein kinase/endoribonuclease IRE1Homo sapiens (human)0.72
Interferon-induced, double-stranded RNA-activated protein kinaseHomo sapiens (human)8
Dual specificity protein kinase TTKHomo sapiens (human)0.8987
Mitogen-activated protein kinase 8Homo sapiens (human)0.921
Mitogen-activated protein kinase 9Homo sapiens (human)1.0111
Tyrosine-protein kinase JAK3Homo sapiens (human)0.957
Mitogen-activated protein kinase 10Homo sapiens (human)1.4193
Mitogen-activated protein kinase 14Homo sapiens (human)0.15

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jiang, M; Li, C; Li, J; Liang, D; Liu, J; Sun, W; Wang, S; Yang, X; Zhang, C; Zhang, M; Zhou, X1
Qu, G; von Schroeder, HP1
Abassi, Y; Daams, R; Fezai, M; Jemaà, M; Kifagi, C; Lang, F; Massoumi, R1

Reviews

1 review(s) available for 2-(4-morpholinoanilino)-6-cyclohexylaminopurine and pyrazolanthrone

ArticleYear
Molecular design and anticancer activities of small-molecule monopolar spindle 1 inhibitors: A Medicinal chemistry perspective.
    European journal of medicinal chemistry, 2019, Aug-01, Volume: 175

    Topics: Antineoplastic Agents; Cell Cycle Proteins; Drug Design; Drug Resistance; Humans; M Phase Cell Cycle Checkpoints; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Spindle Apparatus; Structure-Activity Relationship; Triple Negative Breast Neoplasms

2019

Other Studies

2 other study(ies) available for 2-(4-morpholinoanilino)-6-cyclohexylaminopurine and pyrazolanthrone

ArticleYear
Preliminary evidence for the dedifferentiation of RAW 264.7 cells into mesenchymal progenitor-like cells by a purine analog.
    Tissue engineering. Part A, 2012, Volume: 18, Issue:17-18

    Topics: Adipogenesis; Animals; Anthracenes; Antigens, Surface; Bone and Bones; Carbocyanines; Cell Dedifferentiation; Cell Line; Endoglin; Flow Cytometry; Humans; Intracellular Signaling Peptides and Proteins; JNK Mitogen-Activated Protein Kinases; Macrophages; Mesenchymal Stem Cells; Mice; Microscopy, Fluorescence; Morpholines; Protein Kinase Inhibitors; Purines; Rats; Reverse Transcriptase Polymerase Chain Reaction; Staining and Labeling; Tissue Scaffolds; X-Ray Microtomography

2012
Reversine inhibits Colon Carcinoma Cell Migration by Targeting JNK1.
    Scientific reports, 2018, 08-07, Volume: 8, Issue:1

    Topics: Animals; Anthracenes; Cell Line; Cell Line, Tumor; Cell Movement; Colonic Neoplasms; Humans; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Mitogen-Activated Protein Kinase 8; Molecular Targeted Therapy; Morpholines; Purines; Tumor Burden; Xenograft Model Antitumor Assays

2018